+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

COPD in America 2023: Understanding the COPD Patient Experience

  • Report

  • 156 Pages
  • April 2023
  • Region: Global
  • Health Union
  • ID: 5943947

Explores COPD Patient Demographics, Quality of Life, Information-Seeking Behaviors, HCP Engagement, and Treatment Experiences

This report provides a comprehensive look at life for those living with COPD. Using detailed quantitative data, it gives a full picture of the COPD patient experience - from symptoms to treatment to HCP relationships to quality of life - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges.

About 14.2 million adults live with COPD in the United States.

COPD in America 2023: Understanding the COPD Patient Experience offers an in-depth look at the COPD patient experience. This large-scale, patient-reported data leverages vital quantitative insights essential to understanding key touchpoints in the COPD patient journey, including condition management, HCP engagement, quality of life, treatment experience and satisfaction, and much more.

What makes this report unique?

Very simply: The focus on patients. This syndicated report is one of the few studies that is based on primary research with diagnosed patients, bringing the patient voice to the forefront.

Valuable insights. Informed decisions.

This report lifts the curtain on life with COPD, giving stakeholders an actionable look at the behaviors, attitudes, perceptions, needs, and experiences of people living with the condition. Data can be used to inform strategic decisions, including product communications, competitive assessments, concept development, landscape analyses, patient journey overlays, and forecasting inputs.

This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information.

The analyst reaches millions of people through its portfolio of 45+ condition-specific online health communities - including COPD.net - to provide information, connection, and support to patients and caregivers in the U.S.

This report includes a deep-dive into:

  • COPD patient demographics
    • Age, gender, ethnicity, marital status, children, employment status, income, location, insurance, and other health conditions
  • Impact of COPD on quality of life
    • Time since diagnosis, severity, impact on quality of life, symptoms experienced, and what patients wish others better understood
  • Information-seeking behaviors
    • Information sources used, plus topics of interest
  • HCP engagement
    • Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used
  • COPD treatment awareness and experiences
    • Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials

Key questions answered in this report:

  • To what extent do people say COPD impacts their overall quality of life?
  • What’s the average number of exacerbations in the past year?
  • What do patients wish others understood about COPD?
  • What percentage of patients see a specialist for COPD treatment?
  • What treatments have the highest aided brand awareness among patients?
  • What percentage of patients use maintenance medications?
  • How many patients feel their COPD is well-controlled on their current treatment plan?
  • What percentage of patients are likely to switch or add new treatments in the next six months?
  • What medications have patients discussed with their HCP?
  • What are the top online resources people with COPD use to find information?
  • What kinds of content and information do patients search for?
  • What percentage of patients search for information on treatment options?


COPD in America 2023: Understanding the COPD Patient Experience consists of:

  • A 20-minute online quantitative survey, covering demographics, comorbidities, quality of life/impact, HCP interactions, as well as treatment awareness, experiences, and discussions
  • Qualitative patient insights from open-ended responses

Additional details:

  • Fielded: January 16, 2023 to April 14, 2023
  • Convenience sample of 4,073 respondents diagnosed with COPD
  • Respondents are age 18+, living in the U.S., and are recruited from the analyst's proprietary online health communities and recruiting partners

Table of Contents


Respondent Demographics

Research Highlights

Condition Status and Quality of Life

  • Severity and Exacerbations
  • Symptoms Experienced
  • Impact on Quality of Life
  • Qualitative Patient Insights

Information-Seeking Behaviors

  • Resources Used to Manage Health
  • Types of Content/Information Sought

Treatment Awareness and Experiences

  • Primary HCP Seen for COPD Care
  • Aided Brand Awareness of Treatments
  • Rescue Medication Usage
  • Maintenance Medication Usage
  • Condition Control on Current Treatment and Clinical Trial Interest
  • Treatment Discussions with HCP

Appendix with All Data Charts and Distributions

Products Mentioned

Brands and treatments mentioned in this report include:

  • Albuterol (generic)/Ventolin®/Proventil® (albuterol)
  • Alupent® (metaproterenol sulfate USP)
  • ProAir® Digihaler® (albuterol sulfate)
  • ProAir® HFA (albuterol sulfate)
  • ProAir® RespiClick (albuterol sulfate)
  • Theo-Dur®/TheolairTM (short-acting theophylline)
  • XOPENEX® (levalbuterol tartrate)
  • Other rescue medication (not listed)
  • ADVAIR DISKUS® (fluticasone propionate and salmeterol)
  • AirDuo® Digihaler® (fluticasone propionate and salmeterol)
  • ANORO® ELLIPTA® (umeclidinium and vilanterol)
  • Arcapta® Neohaler® (indacaterol)
  • ATROVENT® HFA (ipratropium bromide HFA)
  • BEVESPI AEROSPHERE® (glycopyrrolate/formoterol fumarate)
  • BREO® ELLIPTA® (fluticasone furoate and vilanterol)
  • BREYNA® (budesonide/formoterol fumarate dihydrate)
  • BREZTRI AEROSPHERE® (budesonide, glycopyrrolate, and formoterol fumarate inhalation aerosol)
  • BROVANA® (arformoterol tartrate)
  • COMBIVENT® RESPIMAT® (ipratropium bromide and albuterol)
  • DULERA® (mometasone furoate and formoterol fumarate dihydrate)
  • Foradil® (formoterol)
  • INCRUSE® ELLIPTA® (umeclidinium)
  • LONHALA® MAGNAIR® (glycopyrrolate)
  • PERFOROMIST® (formoterol)
  • Pulmicort (budesonide)
  • SEEBRI® NEOHALER® (glycopyrrolate)
  • SEREVENT® (salmeterol)
  • SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder)
  • SPIRIVA® RESPIMAT® (tiotropium bromide)
  • STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol)
  • STRIVERDI® RESPIMAT® (olodaterol)
  • SYMBICORT® (budesonide/formoterol fumarate dihydrate)
  • Theo-24®/Uni-Dur (extended-release theophylline)
  • TRELEGY™ ELLIPTA® (fluticasone furoate, umeclidinium, and vilanterol inhalation powder)
  • TUDORZA® PRESSAIR® (aclidinium bromid)
  • UTIBRON® NEOHALER® (indacaterol and glycopyrrolate)
  • YUPELRI™ (revefenacin)
  • Other maintenance medication (not listed)
  • Hailie® (sensor and app)
  • Propeller (sensor and app)
  • Digihaler® (app that can be used with Dighaler® inhalers)
  • DALIRESP® (roflumilast)
  • PROLASTIN®-C (alpha1-proteinase inhibitor [human])
  • Oxygen therapy
  • Oral corticosteroids/steroids (eg, prednisone, Deltasone®, DECADRON®, dexamethasone)
  • Nebulized medication treatments (nebulizer)
  • Other medication (not listed)